Present one-year follow-up data for European AMT-130 study

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 8 Aug 2022
Due: 31 Dec 2023
Delivered: 19 Dec 2023

Deadline
Met
Late
Not met
Today

What the company said

“Company continues to expect to present one-year follow-up data in 2023”

SourceuniQure N.V. Form 8-K press release, 2022-08-08
FilingSEC filing index
Deadline as stated2023
Deadline used31 Dec 2023, the last day of the stated period
TypeProject
Permanent referenceKI-C-2022-QURE-001811
Cite as https://keptindex.org/c/KI-C-2022-QURE-001811/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced updated interim data for its ongoing U.S. and European AMT-130 clinical trials in December 2023, which included follow-up data exceeding the one-year requirement.

A
uniQure N.V. 10-K filed 2024-02-28 Regulatory filing · published 28 Feb 2024 · retrieved 1 Oct 2026 · kept permanently by the SEC
“On December 19, 2023 ,we announced updated interim data, including up to 30 months of follow-up from 39 patients enrolled in the ongoing U.S. and European Phase I/II clinical trials” ✓ confirmed on the page

Market reaction: the shares moved -18.4% against the S&P 500 over the three sessions around the disclosure (27 Feb 2024 to 1 Mar 2024). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +639 days
2 versions

Version 1 · original · stated 8 Aug 2022

Deadline 31 Dec 2023 (“2023”) · wording expected
Version 2 · stated 9 May 2025

Deadline 30 Sep 2025 (“the third quarter of 2025”) · wording expected

“In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Present
Deliverable: Follow-up data presentation
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.